This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Why Is Exelixis (EXEL) Up 10.6% Since Last Earnings Report?
by Zacks Equity Research
Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Top 5 High-Flying Mid-Cap Stocks Despite a Volatile August
by Nalak Das
We have narrowed our search to five mid-cap stocks that have provided double-digit returns in the past month. These are: FN, FRSH, HRB, EXEL, PSN.
Exelixis (EXEL) Late-Stage Study in Pancreatic Tumors Positive
by Zacks Equity Research
Exelixis' (EXEL) phase III CABINET study shows dramatic improvement in efficacy in advanced pancreatic neuroendocrine tumors and advanced extra-pancreatic neuroendocrine tumors.
Exelixis' (EXEL) Prostate Cancer Study Meets Primary Endpoint
by Zacks Equity Research
Exelixis (EXEL) and partner Ipsen's phase III CONTACT-02 study meets one of the two primary endpoints in prostate cancer patients.
EXEL or ILMN: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
EXEL vs. ILMN: Which Stock Is the Better Value Option?
Here's Why Exelixis (EXEL) is a Strong Value Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Surging Earnings Estimates Signal Upside for Exelixis (EXEL) Stock
by Zacks Equity Research
Exelixis (EXEL) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
ANI Pharmaceuticals, Inc. (ANIP) Hit a 52 Week High, Can the Run Continue?
by Zacks Equity Research
ANI (ANIP) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Exelixis (EXEL) Q2 Earnings Top, Cabometyx Drives Growth
by Zacks Equity Research
Exelixis (EXEL) beats second-quarter 2023 earnings and sales estimates as Cabometyx drives growth in approved indications.
Exelixis (EXEL) Reports Q2 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
The headline numbers for Exelixis (EXEL) give insight into how the company performed in the quarter ended June 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Exelixis (EXEL) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Exelixis (EXEL) delivered earnings and revenue surprises of 40.91% and 4.74%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Drug, Biotech Stocks' Q2 Earnings Due on Aug 1: PFE, MRK & More
by Ahan Chakraborty
Let's look at five big biotech, pharma companies, PFE, MRK, VRTX, EXEL and INCY, slated to release quarterly results on Aug 1.
Adaptive Biotechnologies (ADPT) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
by Zacks Equity Research
Adaptive Biotechnologies (ADPT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?
by Zacks Equity Research
Sector ETF report for FBT
EXEL or RGEN: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
EXEL vs. RGEN: Which Stock Is the Better Value Option?
Exelixis (EXEL) Reports Next Week: What You Should Expect
by Zacks Equity Research
Exelixis (EXEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FBT
Why Is Exelixis (EXEL) Down 0.6% Since Last Earnings Report?
by Zacks Equity Research
Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?
by Zacks Equity Research
Sector ETF report for FBT
Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FBT
Exelixis (EXEL) Q1 Earnings Miss, Revenues Increase Y/Y
by Zacks Equity Research
Exelixis (EXEL) misses first quarter 2023 earnings and sales estimates, but product sales increase year over year.
Compared to Estimates, Exelixis (EXEL) Q1 Earnings: A Look at Key Metrics
by Zacks Equity Research
The headline numbers for Exelixis (EXEL) give insight into how the company performed in the quarter ended March 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Exelixis (EXEL) Lags Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Exelixis (EXEL) delivered earnings and revenue surprises of -30.43% and 4.47%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Biotech Stocks' Q1 Earnings on May 9: NVAX, EBS & More
by Kinjel Shah
Let us look at five biotech companies, NVAX, EBS, BLUE, EXEL and NKTR, which are gearing up for their earnings release.
GSK (GSK) Tops Q1 Earnings Estimates
by Zacks Equity Research
Glaxo (GSK) delivered earnings and revenue surprises of 5.88% and 1.28%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?